I have been on he inside in BP for almost 25 years and have seen everything that can happen to a drug. Seeing a patient undergo an unexpected seriousness adverse event is never easy, but do keep it in perspective. There was only this one recent case reported in post marketing surveillance and that's it, there was one previous case in the literature. It looks like relative risk increased by 100% because the number of cases double for one to two, but the absolute numbers are minimal.. The absolute risk of such an event happen again is minimal. Also please keep in mind that patients are predisposed to this already, and it's relationship to therapy may never be seen. Hats off to INCY for disclosing this case, it only makes me want to support this ethical company more. It's a great time to buy.